Pharmaceutical Formulation Patents: Top Companies & Trends 2026
- No single filer dominates. the ranked leader holds 10,576 records but the top 5 combined account for only 8.7% of all 560,336 records in scope.
- Filings peaked in 2021 at 977 and fell 49% to 498 by 2024, the last year the data can be treated as complete.
- A61K carries the field at 3.3% of all records, while device- and container-side classes such as A61M and A61J sit under 0.1% each — a sign of where claim density thins out.
Filing growth compares 2021 (977 records) with 2024 (498) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 560,336 records in scope (CR5), not by the ranked leaders only.
A wide, shallow field with a long tail of single-filing entrants
Pharmaceutical formulation patenting spans everything from controlled-release matrices to antibody stabilisation, and the record set reflects that breadth: 560,336 records filed between 2015 and the 2026 cut-off, drawn from a search string anchored on formulation terms crossed with release-kinetics and stability language. The assignee ranking runs 100 companies deep, and even the leader’s 10,576 records represent a small fraction of the whole — this is not a field one or two firms have locked up.
Filing activity rose through the late 2010s, peaked in 2021, and has since declined through the most recent complete year. Because publication lags filing by roughly 18 months, the last one or two years in any chart will always look lower than they will eventually settle — that drop should not be read as the field cooling in real time.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
The two views below cover the same 560,336-record dataset from different angles: one tracks filing volume over time, the other breaks the corpus down by IPC subclass so you can see where formulation claims concentrate.
Filings rose to a 2021 peak, then eased back
Annual filings climbed from 752 in 2017 to a peak of 977 in 2021, then declined to 498 by 2024 — a 49% drop over that span. Treat 2025 and 2026 figures as provisional; publication lag means recent years understate true filing activity.
A61K dominates; device and container classes are thin
A61K (medicinal preparations) appears on 3.3% of all records, well ahead of A61P (therapeutic activity, 1.4%) and the heterocyclic- and peptide-chemistry classes further down. Device-adjacent classes like A61M (body-fluid devices) and A61J (medicine containers) each sit at 0.1%, marking areas where formulation claims rarely extend into delivery hardware or packaging.
Shares are the percentage of the 560,336 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Pharmaceutical Formulation Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about pharmaceutical formulation patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
AU2025237950A1 — Pharmaceutical formulation and system and method for delivery
A sustained-release formulation for pain management disperses an active ingredient within a water-miscible, hygroscopic network-forming material, optionally combined with a hydrophobic component and a reinforcing member to extend delivery further.Filed by Rilento Pharma, LLC and published 2025-10-16.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6171586B1 | Antibody formulation | 3,393 |
| 2 | US5674533A | Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension | 3,280 |
| 3 | US20040109865A1 | Antibody composition-containing medicament | 2,517 |
| 4 | US5641515A | Controlled release biodegradable nanoparticles containing insulin | 1,398 |
| 5 | US5133974A | Extended release pharmaceutical formulations | 1,265 |
| 6 | US6139865A | Taste-masked microcapsule compositions and methods of manufacture | 1,087 |
| 7 | US5922356A | Sustained release formulation | 1,075 |
| 8 | US5891474A | Time-specific controlled release dosage formulations and method of preparing same | 1,064 |
| 9 | US20030077297A1 | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents | 1,039 |
| 10 | US5508042A | Controlled release oxycodone compositions | 759 |
Ranked by citation count within the searched corpus. Older records accumulate more citations simply by being available longer, so treat this as a signal of influence on later filings, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about the state of the field
Three patterns stand out once filing volume, citation weight and technology composition are laid side by side.
Leadership is real but not exclusive
The top 5 assignees combined account for 8.7% of all records in scope, and the top 10 for 14.5%. That leaves the large majority of filings spread across a long tail of the ranked leaders and unranked entrants — useful context before assuming any one company controls the space.
Volume has eased from its 2021 high
Filings peaked at 977 in 2021 and fell to 498 by 2024, the most recent year with complete data. That decline sits inside a broader pattern of formulation filings rising through the 2010s and cooling since — not a sign the underlying science has stalled.
Medicinal-preparation claims anchor the field
A61K carries more than double the share of the next-largest class, A61P. Chemistry-heavy classes like C07D and C07K sit well below 1%, and delivery-hardware classes such as A61M and A61J are thinner still — the claim density is concentrated in preparation composition rather than delivery devices.
The most-cited prior art is decades old
The single most-cited record in this corpus is an antibody formulation patent, followed closely by a controlled-release liquid suspension formulation. High citation counts here reflect long availability for later filers to cite, not that these approaches remain the state of the art.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to pharmaceutical formulation patent landscape, with the prior art for and against each one.
Who is filing, and where momentum has cooled
The ranked leaders span large-molecule and small-molecule specialists alike, but recent-year momentum data shows filing activity easing across several of them — consistent with the field-wide decline from its 2021 peak.
Broad-portfolio leaders file across preparation types
The top-ranked assignee's filing volume outpaces the field but still represents a small share of total records, reflecting a market where formulation innovation is distributed across many originators rather than concentrated in a handful of labs.
Several established filers show zero latest-year activity
Recent-year momentum data shows multiple ranked assignees, including large branded originators, recording no filings in the latest year — a pattern consistent with publication lag rather than an actual halt in R&D.
Co-filing is rare and concentrated in academic-industry links
Only 10 co-assignee pairs appear in the dataset, the strongest linking a university system to a specialist therapeutics partner. Co-assignment is the exception here, not the norm — most formulation IP is filed by a single entity.
| Assignee | Recent year | YoY |
|---|---|---|
| AstraZeneca AB | 1 | -50% |
| The Board of Regents of the University of Texas System | 0 | -100% |
| Chiesi Farmaceutici S.p.A. | 0 | -100% |
| Grünenthal GmbH | 0 | — |
| Glaxo Group Limited | 0 | — |
| Novartis AG (Switzerland) | 0 | — |
| Eli Lilly & Co. | 0 | -100% |
| Pharmazan Inc. | 0 | — |
Where to take this analysis
The dataset points to a field with room to file outside the dense preparation-chemistry core. These next steps narrow that down to specific claim strategy.
Map claim space before drafting
Before filing in A61K-heavy territory, check citation density against the most-cited records to see which formulation approaches are already heavily fenced.
Explore claim mapping in EurekaTrack momentum, not just volume
A leader's raw filing count can mask a cooling trajectory. Cross-check any target assignee's recent-year momentum before assuming continued activity.
Run an assignee momentum check in EurekaProbe the under-claimed branches
Device- and container-adjacent classes carry a fraction of the filing density of core preparation classes — a starting point for freedom-to-operate work.
Search white space in EurekaCommon questions about pharmaceutical formulation patents
The ranked leader in this dataset holds 10,576 records, well ahead of the field, but concentration is modest overall: the top 5 assignees combined hold only 8.7% of the 560,336 records in scope, and the top 10 hold 14.5%. That means the majority of formulation filings sit outside the leading group, spread across the rest of the 100-company ranking and unranked filers. No single company's portfolio should be treated as covering the field.
Filings rose through the late 2010s, peaked in 2021 at 977, and had fallen to 498 by 2024 — a 49% decline over that three-year span, the most recent period the data can be treated as complete. Figures for 2025 and 2026 look lower still, but that is largely an artefact of publication lag, which runs roughly 18 months behind actual filing. The honest read is a field that cooled off its 2021 high, not one that has stopped moving.
A61K, covering medicinal preparations, is the largest single class at 3.3% of all 560,336 records, more than double the next largest class, A61P (therapeutic activity of compounds) at 1.4%. Chemistry-focused classes such as C07D (heterocyclic compounds) and C07K (peptides and proteins) sit under 0.5% each. Device- and container-related classes, A61M and A61J, are thinner still at roughly 0.1% each, suggesting formulation claims rarely extend deep into delivery hardware or packaging design.
The thinnest filing density sits in classes adjacent to the formulation core rather than within it — body-fluid delivery devices (A61M) and medicine containers (A61J) each account for only about 0.1% of records, compared with 3.3% for medicinal preparations generally. That gap suggests opportunities in claims that bridge formulation chemistry with delivery hardware or packaging interaction, areas that are technically adjacent but not heavily claimed today.
Very little. The dataset records only 10 co-assignee pairs across the entire corpus, with the strongest pair linking a university research foundation to a specialist pharmaceutical partner. The overwhelming majority of pharmaceutical formulation patents are filed by a single assignee, which means joint-venture or licensing signals in this space are the exception rather than something to expect as a matter of course.
Research Pharmaceutical Formulation Patent Landscape in depth with Eureka
Go past this page: query the whole pharmaceutical formulation patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.